The Role of VEGF receptors as molecular target in nuclear medicine for cancer diagnosis and combination therapy
K Masłowska, PK Halik, D Tymecka, A Misicka… - Cancers, 2021 - mdpi.com
Simple Summary The rapid development of diagnostic and therapeutic methods of the
cancer treatment causes that these diseases are becoming better known and the fight …
cancer treatment causes that these diseases are becoming better known and the fight …
Post-elution processing of 44Ti/44Sc generator-derived 44Sc for clinical application
M Pruszyński, NS Loktionova, DV Filosofov… - Applied Radiation and …, 2010 - Elsevier
The 44Ti/44Sc (T1/244Ti= 60a) generator provides cyclotron-independent access to
positron-emitting 44Sc (T1/2= 3.97 d) for PET imaging. This work aims to post-elution …
positron-emitting 44Sc (T1/2= 3.97 d) for PET imaging. This work aims to post-elution …
Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy
E Seregni, M Maccauro, C Chiesa, L Mariani… - European journal of …, 2014 - Springer
Purpose Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin
analogues has been demonstrated to be an effective therapeutic option in patients with …
analogues has been demonstrated to be an effective therapeutic option in patients with …
213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model
JP Norenberg, BJ Krenning, IRHM Konings… - Clinical Cancer …, 2006 - AACR
Purpose: The somatostatin analogue [DOTA0, Tyr3] octreotide (DOTATOC) has previously
been labeled with low linear energy transfer (LET) β-emitters, such as 177Lu or 90Y, for …
been labeled with low linear energy transfer (LET) β-emitters, such as 177Lu or 90Y, for …
Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours
K Öberg, B Eriksson - Best Practice & Research Clinical Endocrinology & …, 2005 - Elsevier
Carcinoid tumours belong to the family of neuroendocrine tumours with a capacity to take up
and concentrate amines and precursors as well as peptides, and can thereby be detected by …
and concentrate amines and precursors as well as peptides, and can thereby be detected by …
Preclinical and clinical studies of peptide receptor radionuclide therapy
SE Pool, EP Krenning, GA Koning… - Seminars in nuclear …, 2010 - Elsevier
In the 1980s, the 111In-labeled somatostatin analog OctreoScan (Covidien, Hazelwood,
MO) was developed for imaging of somatostatin receptor subtype 2 (sst2) overexpressing …
MO) was developed for imaging of somatostatin receptor subtype 2 (sst2) overexpressing …
Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments
SM Bison, MW Konijnenberg, M Melis, SE Pool… - Clinical and translational …, 2014 - Springer
Peptide receptor radionuclide therapy (PRRT) has been shown to be an effective treatment
for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs …
for neuroendocrine tumors (NETs) if curative surgery is not an option. A majority of NETs …
Peptide receptor radionuclide therapy of neuroendocrine tumours
T Brabander, JJM Teunissen, CHJ Van Eijck… - Best practice & research …, 2016 - Elsevier
In the past decades, the number of neuroendocrine tumours that are detected is increasing.
A relative new and promising therapy for patients with metastasised or inoperable disease is …
A relative new and promising therapy for patients with metastasised or inoperable disease is …
Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys
M Béhé, G Kluge, W Becker, M Gotthardt… - Journal of Nuclear …, 2005 - Soc Nuclear Med
Uptake of radiolabeled peptides in the kidneys may obscure abdominal tumors in
radiopeptide scintigraphy. This problem is much more pronounced in peptide receptor …
radiopeptide scintigraphy. This problem is much more pronounced in peptide receptor …
A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
F Forrer, H Uusijärvi, C Waldherr, M Cremonesi… - European journal of …, 2004 - Springer
Abstract [Yttrium-90-DOTA-Tyr 3]-octreotide (DOTATOC) and [177 Lu-DOTA-Tyr 3-Thr 8]-
octreotide (DOTATATE) are used for peptide receptor-mediated radionuclide therapy …
octreotide (DOTATATE) are used for peptide receptor-mediated radionuclide therapy …